The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).

The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-κB-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.

A graft copolymer comprising: a core polymer comprising a crosslinked or non-crosslinked polysaccharide, a plurality of primary graft polymers covalently grafted to the core polymer, a plurality of secondary graft polymers covalently grafted to each primary graft polymer, an injectable dermal aesthetic formulation comprising such a graft copolymer and a method of preparing such a graft copolymer.

The invention relates to chitin, a hydrolysate and a method for the production of at least one desired product from insects. More specifically, the invention relates to a method for the production of chitin and/or chitosan from insect cuticles, comprising a step in which insect cuticles are treated with an oxidising agent, followed by a step involving the enzymatic hydrolysis of the insect cuticles using a proteolytic enzyme.

Provided herein is chitosan dually derivatized with arginine and gluconic acid; and methods of making and using the same, e.g., for gene delivery in vivo.

The present invention is a product and process to produce a new inclusion of a Chitosan-based compound and herbal extract, to provide consistent and long-lasting antimicrobial, antiviral, antibacterial, antifungal, anti-spore, and anti-odor characteristics.

A method of preparing a hydrogel product including crosslinked glycosaminoglycan molecules, said method including: i) providing a glycosaminoglycan crosslinked by amide bonds, wherein the crosslinked glycosaminoglycans include residual amine groups; and ii) acylating residual amine groups of the crosslinked glycosaminoglycans provided in i) to form acylated crosslinked glycosaminoglycans.

A process for producing a composition comprising a crosslinked hydrogel is proposed. The process comprises providing a container body (2), wherein the container body (2) has a body inner wall (21) and a body outer wall (22), wherein the body inner (21) wall is configured to be tempered, filling of a fluid (7) comprising at least a mixture of a polymer and water into the container body (2), and agitating the fluid. For crosslinking of the fluid (7), a container insert (3) is provided, the container insert (3) having an insert outer wall (32) which is configured to be tempered and a container assembly (1) is formed by inserting the container insert (3) into the container body (2) so that the insert outer wall (32) of the container insert (3) and the body inner wall (21) of the container body (2) are separated by a gap (9) of constant width and define a volume (6) for receiving the fluid (7). Crosslinking of the fluid (7) is then performed while tempering the insert outer wall (32) and the body inner wall (21) to form a crosslinked hydrogel.

The present invention provides a hyaluronic acid derivative containing a disaccharide unit represented by formula (I) or formula (I) and (II), and a complex containing the hyaluronic acid derivative and a drug.

A sulfhydryl modified hyaluronic acid has a high mercaptan content, and a small change in the molecular mass of the main chain molecule, and has a significantly improved viscosity, water retention, and oxidation resistance. It is prepared from hyaluronic acid modified by acryl-based compounds and polysulfhydryl compounds by means of the Michael addition reaction of mercaptan and conjugated double bonds. The preparation method can flexibly control the structure and composition of a synthesized product, the type and content of the terminal functional group of a large number of compound molecules, etc. The use of a reagent having high biocompatibility effectively controls the production cost and reduces the toxicity during the synthesis.